{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
methyl salicylate
to a specific field?
Status:
Class (Stereo):
CHEMICAL (ACHIRAL)
Fosfocreatinine, a cardioprotectant that was used for the treatment of cardiac disorders. Information about the current use of this drug is not available.
Class (Stereo):
CHEMICAL (RACEMIC)
FLOTRENIZINE, a diarylmethylpiperazine derivative, is an antihistaminic agent.
Class (Stereo):
CHEMICAL (ACHIRAL)
Cinoquidox is a quinoxaline derivative used in veterinary as an antibacterial agent and growth promotor. It was patented by Ciba-Geigy Corporation and was claimed to be effective in the case of diseases of the respiratory tract in poultry, and infections of the intestinal tract and of the urogenital system in domestic animals and productive livestock.
Class (Stereo):
CHEMICAL (ACHIRAL)
Nifurvidine, a 5-nitrofuran derivative, is an antibacterial agent. It was used for controlling Salmonella choleraesuis in swine. The mode of action of 5-nitrofuran analogues is based on red-ox biotransformation.
Class (Stereo):
CHEMICAL (RACEMIC)
Draquinolol is a cardioselective beta-adrenoceptor antagonist with a long duration of action in vivo. The long duration of action of draquinolol in vivo is due to the formation of a tight complex with beta 1-adrenoceptors. Draquinolol reduced an exercise tachycardia.
Status:
Investigational
Source:
NCT01033097: Phase 2 Interventional Completed Pruritus in Patients With Atopic Dermatitis
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Class (Stereo):
CHEMICAL (ACHIRAL)
Indanidine is a selective and effective α2-antagonist, α1-partial agonist patented by pharmaceutical company Siegfried A.-G as a low toxic compound with direct hypotensive action. Indanidine does not penetrate the blood-brain barrier, does not induce drug-metabolizing enzymes in the liver, does not cause behavioral changes.
Status:
Investigational
Source:
INN:tauroselcholic acid [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT01407874: Phase 2 Interventional Completed Gout
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Ulodesine (BCX4208) is a new, orally active, highly potent inhibitor of purine nucleoside phosphorylase (PNP) for the treatment of hyperuricemia and gout. Inhibition of PNP reduces the substrates available for XO to form uric acid. The drug is currently under development for the management of hyperuricemia in chronic gout. Two Phase II clinical trials have shown promising results regarding urate-lowering effect in both as monotherapy and in combination with allopurinol. Ulodesine shows no interaction with CYP450 isoforms and has no hepatic metabolism; therefore, no drug interactions were expected. Following the successful outcome of the Phase IIb clinical trial, Phase III development of ulodesine is planned. One concern regarding the use of ulodesine is its impact on T cells. Lack of PNP is associated with immunodeficiency and autoimmune disorders.
Status:
Investigational
Source:
INN:pazelliptine [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Pazelliptine (previously known as BD 40 or SR 95225A) was developed as an antitumor drug that binds to the DNA sequence, preferable to G-C rich region and thus produces cellular DNA lesions. This drug was undergoing phase II trials in France for the treatment of cancer. However, this study was discontinued.
